1. Home
  2. CRSP vs MRCY Comparison

CRSP vs MRCY Comparison

Compare CRSP & MRCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$56.70

Market Cap

5.6B

Sector

Health Care

ML Signal

HOLD

Logo Mercury Systems Inc

MRCY

Mercury Systems Inc

HOLD

Current Price

$75.68

Market Cap

4.5B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
MRCY
Founded
2013
1981
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
4.5B
IPO Year
2016
1998

Fundamental Metrics

Financial Performance
Metric
CRSP
MRCY
Price
$56.70
$75.68
Analyst Decision
Buy
Buy
Analyst Count
19
7
Target Price
$71.50
$76.43
AVG Volume (30 Days)
1.8M
644.5K
Earning Date
02-10-2026
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$38,337,000.00
$932,798,000.00
Revenue This Year
N/A
$6.47
Revenue Next Year
$723.84
$8.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.63
52 Week Low
$30.04
$39.42
52 Week High
$78.48
$85.33

Technical Indicators

Market Signals
Indicator
CRSP
MRCY
Relative Strength Index (RSI) 51.43 58.87
Support Level $54.50 $68.81
Resistance Level $59.18 $77.56
Average True Range (ATR) 2.87 2.72
MACD 0.33 0.35
Stochastic Oscillator 44.03 79.03

Price Performance

Historical Comparison
CRSP
MRCY

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About MRCY Mercury Systems Inc

Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.

Share on Social Networks: